Despite advances in our understanding of disease mechanisms, such as the FLT3 inhibitor gilteritinib57,58, IDH1/2 inhibitors ivosidenib59 and enasidenib60 and BCL2 inhibitor venetoclax61,62, offering considerable effect for AML, the outcome of most AML patients remains poor. Here, BCL2 is linked to acute myeloid leukemia.